Recruitment

Recruitment Status
Not yet recruiting
Estimated Enrollment
57

Summary

Conditions
Esophageal Cancer
Type
Interventional
Phase
Phase 2
Design
Allocation: Non-RandomizedIntervention Model: Parallel AssignmentMasking: None (Open Label)Primary Purpose: Treatment

Participation Requirements

Age
Between 18 years and 75 years
Gender
Both males and females

Description

This is an open clinical study to evaluate the efficacy and safety of Camrelizumab combined with Concurrent Radiotherapy and Chemotherapy in the first-line treatment of locally recurrent esophageal cancer. Objective to study patients with local recurrence of esophageal cancer after radical treatment...

This is an open clinical study to evaluate the efficacy and safety of Camrelizumab combined with Concurrent Radiotherapy and Chemotherapy in the first-line treatment of locally recurrent esophageal cancer. Objective to study patients with local recurrence of esophageal cancer after radical treatment. The study will take progression free survival (PFS) as the main efficacy index, and plan to enroll about 236 patients with local recurrence of esophageal cancer after radical treatment. After fully informed and signed the informed consent, the subjects will enter the experimental stage after screening.

Tracking Information

NCT #
NCT04390945
Collaborators
Not Provided
Investigators
Not Provided